Sarepta has seen its share price crater and faces looming competition
Kristoffer Tripplaar/Sipa via AP
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Sarepta Therapeutics, the bruised maker of Duchenne muscular dystrophy treatments, on Monday named Michael Severino, formerly the CEO of Tessera Therapeutics, as its new chief executive, starting Tuesday.
Severino is replacing Doug Ingram, who announced earlier this year that he planned to retire after leading the biotech for nearly a decade. During his tenure, the company got three Duchenne treatments approved, but has faced ongoing questions about how effective they are and run into regulatory scrutiny over the safety of its gene therapy.
